Hosted on MSN1mon
AbbVie, Neomorph to develop molecular glue degraders
AbbVie (NYSE:ABBV) has entered into a collaboration agreement with Neomorph for the development of novel molecular glue degraders for multiple targets across oncology and immunology. Under the ...
GlobalData on MSN4mon
Biogen and Neomorph enter molecular glue degrader deal
Biogen and Neomorph have entered a research partnership aimed at discovering and developing molecular glue degraders for the ...
pharmaphorum1y
Novo Nordisk joins molecular glue club with Neomorph deal
That differentiates them from some other protein degrader technologies that still need a binding site ... San Diego, California-based Neomorph was set up in 2020 by investment group Deerfield ...